| NCT03409432 |
Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03409432 |
Recruiting |
Ohio State University Comprehensive Cancer Center |
2021-04-30 |
| NCT03380026 |
Mechlorethamine Induced Contact Dermatitis Avoidance Study |
https://ClinicalTrials.gov/show/NCT03380026 |
Recruiting |
Rochester Skin Lymphoma Medical Group, PLLC |
2019-12-13 |
| NCT03357224 |
PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL) |
https://ClinicalTrials.gov/show/NCT03357224 |
Recruiting |
European Organisation for Research and Treatment of Cancer - EORTC |
2021-09-30 |
| NCT03340155 |
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases |
https://ClinicalTrials.gov/show/NCT03340155 |
Recruiting |
Medical University of Graz |
2022-10-31 |
| NCT03292406 |
A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) |
https://ClinicalTrials.gov/show/NCT03292406 |
Active, not recruiting |
Galderma R&D |
2020-09-30 |
| NCT03278782 |
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin |
https://ClinicalTrials.gov/show/NCT03278782 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-11-30 |
| NCT03218683 |
Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. |
https://ClinicalTrials.gov/show/NCT03218683 |
Active, not recruiting |
AstraZeneca |
2022-01-11 |
| NCT03192202 |
AFM13 in Relapsed/Refractory Cutaneous Lymphomas |
https://ClinicalTrials.gov/show/NCT03192202 |
Recruiting |
Columbia University |
2020-08-31 |
| NCT03116659 |
CTCL Directed Therapy |
https://ClinicalTrials.gov/show/NCT03116659 |
Recruiting |
James J. Peters Veterans Affairs Medical Center |
2020-12-30 |
| NCT03109353 |
Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease |
https://ClinicalTrials.gov/show/NCT03109353 |
Active, not recruiting |
St. Olavs Hospital |
2020-09-30 |
| NCT03017820 |
VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03017820 |
Recruiting |
Mayo Clinic |
2021-01-15 |
| NCT03011814 |
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03011814 |
Recruiting |
City of Hope Medical Center |
2023-03-08 |
| NCT02978625 |
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers |
https://ClinicalTrials.gov/show/NCT02978625 |
Recruiting |
National Cancer Institute (NCI) |
2021-06-01 |
| NCT02689453 |
Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) |
https://ClinicalTrials.gov/show/NCT02689453 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2023-01-31 |
| NCT02676778 |
Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02676778 |
Completed |
Eisai Inc. |
2019-04-24 |
| NCT02643303 |
A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers |
https://ClinicalTrials.gov/show/NCT02643303 |
Recruiting |
Ludwig Institute for Cancer Research |
2022-08-31 |
| NCT02616965 |
A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02616965 |
Recruiting |
Fox Chase Cancer Center |
2021-12-31 |
| NCT02593045 |
Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) |
https://ClinicalTrials.gov/show/NCT02593045 |
Active, not recruiting |
Innate Pharma |
2019-12-31 |
| NCT02576496 |
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02576496 |
Recruiting |
Mundipharma-EDO GmbH |
2021-03-31 |
| NCT02567656 |
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02567656 |
Completed |
Rhizen Pharmaceuticals SA |
2018-03-31 |
| NCT02546440 |
Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL) |
https://ClinicalTrials.gov/show/NCT02546440 |
Recruiting |
Universitätsmedizin Mannheim |
2020-09-30 |
| NCT02542124 |
NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) |
https://ClinicalTrials.gov/show/NCT02542124 |
Active, not recruiting |
Neumedicines Inc. |
2019-02-28 |
| NCT02520791 |
Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02520791 |
Recruiting |
National Cancer Institute (NCI) |
2020-12-31 |
| NCT02512497 |
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT02512497 |
Recruiting |
Ohio State University Comprehensive Cancer Center |
2020-12-31 |
| NCT02448381 |
FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) |
https://ClinicalTrials.gov/show/NCT02448381 |
Active, not recruiting |
Soligenix |
2019-12-31 |
| NCT02342782 |
Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02342782 |
Active, not recruiting |
City of Hope Medical Center |
2020-12-31 |
| NCT02341209 |
Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02341209 |
Recruiting |
Rochester General Hospital |
2020-02-06 |
| NCT02232516 |
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02232516 |
Recruiting |
Northwestern University |
2022-07-31 |
| NCT02192021 |
Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) |
https://ClinicalTrials.gov/show/NCT02192021 |
Recruiting |
University of Pittsburgh |
2021-12-31 |
| NCT03385226 |
A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) |
https://ClinicalTrials.gov/show/NCT03385226 |
Recruiting |
University College, London |
2022-01-31 |
| NCT02181218 |
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas |
https://ClinicalTrials.gov/show/NCT02181218 |
Active, not recruiting |
Washington University School of Medicine |
2019-03-28 |
| NCT02168140 |
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02168140 |
Active, not recruiting |
Wake Forest University Health Sciences |
2019-04-18 |
| NCT01273766 |
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01273766 |
Completed |
Wake Forest University Health Sciences |
2012-03-31 |
| NCT02811783 |
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL |
https://ClinicalTrials.gov/show/NCT02811783 |
Recruiting |
Elorac, Inc. |
2022-06-30 |
| NCT01959477 |
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01959477 |
Completed |
Case Comprehensive Cancer Center |
2015-01-31 |
| NCT01902225 |
Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01902225 |
Completed |
University of California, San Francisco |
2018-07-13 |
| NCT01871727 |
A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01871727 |
Recruiting |
Eisai Inc. |
2021-03-31 |
| NCT01805037 |
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas |
https://ClinicalTrials.gov/show/NCT01805037 |
Active, not recruiting |
Northwestern University |
2021-01-31 |
| NCT01804335 |
CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL) |
https://ClinicalTrials.gov/show/NCT01804335 |
Completed |
M.D. Anderson Cancer Center |
2015-03-31 |
| NCT01800838 |
Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01800838 |
Completed |
Case Comprehensive Cancer Center |
2014-09-30 |
| NCT01760655 |
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01760655 |
Recruiting |
Thomas Jefferson University |
2021-03-31 |
| NCT01748721 |
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT01748721 |
Completed |
Morphotek |
2015-05-31 |
| NCT01728805 |
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL |
https://ClinicalTrials.gov/show/NCT01728805 |
Active, not recruiting |
Kyowa Kirin Pharmaceutical Development, Inc. |
2017-03-31 |
| NCT01678443 |
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01678443 |
Active, not recruiting |
Fred Hutchinson Cancer Research Center |
2011-04-11 |
| NCT01676831 |
Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL) |
https://ClinicalTrials.gov/show/NCT01676831 |
Completed |
Abramson Cancer Center of the University of Pennsylvania |
2015-01-31 |
| NCT01658319 |
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01658319 |
Completed |
Case Comprehensive Cancer Center |
2015-02-28 |
| NCT01638533 |
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT01638533 |
Active, not recruiting |
National Cancer Institute (NCI) |
2018-11-29 |
| NCT01588015 |
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01588015 |
Active, not recruiting |
City of Hope Medical Center |
2021-11-30 |
| NCT01578499 |
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician’s Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) |
https://ClinicalTrials.gov/show/NCT01578499 |
Completed |
Takeda |
2016-05-31 |
| NCT01569724 |
Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01569724 |
Completed |
Rennes University Hospital |
2016-12-31 |
| NCT01567709 |
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01567709 |
Completed |
National Cancer Institute (NCI) |
2018-03-29 |
| NCT01529827 |
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01529827 |
Completed |
Roswell Park Cancer Institute |
2015-05-28 |
| NCT01523223 |
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01523223 |
Completed |
Stanford University |
2016-09-30 |
| NCT01486277 |
A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01486277 |
Completed |
Janssen Research & Development, LLC |
2014-11-30 |
| NCT01484015 |
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia |
https://ClinicalTrials.gov/show/NCT01484015 |
Completed |
Wake Forest University Health Sciences |
2012-06-30 |
| NCT01433731 |
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL) |
https://ClinicalTrials.gov/show/NCT01433731 |
Completed |
TetraLogic Pharmaceuticals |
2013-09-30 |
| NCT01427881 |
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01427881 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-06-30 |
| NCT01396070 |
Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level |
https://ClinicalTrials.gov/show/NCT01396070 |
Completed |
Stanford University |
2015-04-30 |
| NCT01384513 |
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01384513 |
Recruiting |
Thomas Jefferson University |
2020-12-31 |
| NCT01352520 |
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) |
https://ClinicalTrials.gov/show/NCT01352520 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2021-01-31 |
| NCT01326702 |
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors |
https://ClinicalTrials.gov/show/NCT01326702 |
Completed |
National Cancer Institute (NCI) |
2015-04-30 |
| NCT04362007 |
A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04362007 |
Recruiting |
Otsuka Pharmaceutical Co., Ltd. |
2024-09-30 |
| NCT04296786 |
Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study |
https://ClinicalTrials.gov/show/NCT04296786 |
Recruiting |
Peking Union Medical College Hospital |
2022-12-31 |
| NCT04045470 |
A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04045470 |
Recruiting |
Dana-Farber Cancer Institute |
2023-01-01 |
| NCT03902184 |
IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03902184 |
Recruiting |
Innate Pharma |
2022-03-01 |
| NCT03837457 |
PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study |
https://ClinicalTrials.gov/show/NCT03837457 |
Enrolling by invitation |
miRagen Therapeutics, Inc. |
2021-12-31 |
| NCT03775525 |
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT03775525 |
Recruiting |
Genzada Pharmaceuticals USA, Inc. |
2020-09-30 |
| NCT03713320 |
SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides |
https://ClinicalTrials.gov/show/NCT03713320 |
Active, not recruiting |
miRagen Therapeutics, Inc. |
2021-04-30 |
| NCT03602157 |
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL |
https://ClinicalTrials.gov/show/NCT03602157 |
Recruiting |
UNC Lineberger Comprehensive Cancer Center |
2026-09-30 |
| NCT03601819 |
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders |
https://ClinicalTrials.gov/show/NCT03601819 |
Recruiting |
University of Michigan Rogel Cancer Center |
2021-09-30 |
| NCT03493451 |
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK- Neoplasms |
https://ClinicalTrials.gov/show/NCT03493451 |
Active, not recruiting |
BeiGene |
2021-02-28 |
| NCT03487133 |
Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03487133 |
Recruiting |
Samsung Medical Center |
2020-12-31 |
| NCT01258998 |
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma |
https://ClinicalTrials.gov/show/NCT01258998 |
Completed |
National Cancer Institute (NCI) |
2014-07-31 |
| NCT01254578 |
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers |
https://ClinicalTrials.gov/show/NCT01254578 |
Completed |
National Cancer Institute (NCI) |
2012-11-09 |
| NCT01233921 |
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT01233921 |
Completed |
Fred Hutchinson Cancer Research Center |
2012-07-31 |
| NCT01226472 |
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001 |
https://ClinicalTrials.gov/show/NCT01226472 |
Completed |
Kyowa Kirin Pharmaceutical Development, Inc. |
2012-09-30 |
| NCT01198665 |
RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas |
https://ClinicalTrials.gov/show/NCT01198665 |
Completed |
Samsung Medical Center |
2014-12-31 |
| NCT01177371 |
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01177371 |
Completed |
Case Comprehensive Cancer Center |
2000-02-29 |
| NCT01158274 |
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT01158274 |
Completed |
National Cancer Institute (NCI) |
2012-08-31 |
| NCT01134341 |
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01134341 |
Completed |
Acrotech Biopharma LLC |
2015-08-31 |
| NCT01129193 |
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma |
https://ClinicalTrials.gov/show/NCT01129193 |
Completed |
Ohio State University Comprehensive Cancer Center |
2017-01-07 |
| NCT01129180 |
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01129180 |
Completed |
Ohio State University Comprehensive Cancer Center |
2012-05-31 |
| NCT01110135 |
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT01110135 |
Completed |
University of Washington |
2013-11-30 |
| NCT01053494 |
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer |
https://ClinicalTrials.gov/show/NCT01053494 |
Completed |
Wake Forest University Health Sciences |
2012-02-29 |
| NCT01007448 |
Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL) |
https://ClinicalTrials.gov/show/NCT01007448 |
Completed |
Bausch Health Americas, Inc. |
2014-02-20 |
| NCT00961220 |
O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00961220 |
Completed |
National Cancer Institute (NCI) |
2012-04-08 |
| NCT00918333 |
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00918333 |
Completed |
Mayo Clinic |
2015-12-01 |
| NCT00896493 |
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00896493 |
Active, not recruiting |
Stanford University |
2022-12-31 |
| NCT00890747 |
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy |
https://ClinicalTrials.gov/show/NCT00890747 |
Completed |
National Cancer Institute (NCI) |
2011-05-31 |
| NCT00856388 |
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders |
https://ClinicalTrials.gov/show/NCT00856388 |
Completed |
Roswell Park Cancer Institute |
2012-08-09 |
| NCT04171791 |
A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL) |
https://ClinicalTrials.gov/show/NCT04171791 |
Recruiting |
Yale University |
2021-02-28 |
| NCT00807495 |
Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00807495 |
Completed |
Takeda |
2011-01-04 |
| NCT02953301 |
Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) |
https://ClinicalTrials.gov/show/NCT02953301 |
Recruiting |
4SC AG |
2022-01-31 |
| NCT02580552 |
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL |
https://ClinicalTrials.gov/show/NCT02580552 |
Active, not recruiting |
miRagen Therapeutics, Inc. |
2020-12-31 |
| NCT01839916 |
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01839916 |
Completed |
University of Chicago |
2018-08-31 |
| NCT00771472 |
Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1) |
https://ClinicalTrials.gov/show/NCT00771472 |
Completed |
Merck Sharp & Dohme Corp. |
2011-07-31 |
| NCT00769288 |
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00769288 |
Completed |
National Cancer Institute (NCI) |
2013-12-31 |
| NCT00748319 |
Killer Immunoglobulin-Like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00748319 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2011-11-30 |
| NCT00744991 |
A Study for Patients With Relapsed Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00744991 |
Completed |
Eli Lilly and Company |
2010-01-31 |
| NCT00660231 |
Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00660231 |
Completed |
University College, London |
2011-09-30 |
| NCT00611208 |
A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) |
https://ClinicalTrials.gov/show/NCT00611208 |
Completed |
Angimmune LLC |
2015-02-28 |
| NCT00608361 |
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery |
https://ClinicalTrials.gov/show/NCT00608361 |
Completed |
National Cancer Institute (NCI) |
2014-08-31 |
| NCT00601718 |
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00601718 |
Completed |
University of Washington |
2010-06-30 |
| NCT00554827 |
Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00554827 |
Completed |
Acrotech Biopharma LLC |
2012-01-31 |
| NCT00536601 |
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors |
https://ClinicalTrials.gov/show/NCT00536601 |
Completed |
Roswell Park Cancer Institute |
2018-07-09 |
| NCT00506129 |
Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00506129 |
Completed |
M.D. Anderson Cancer Center |
2015-06-30 |
| NCT00501735 |
Forodesine in the Treatment of Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00501735 |
Completed |
BioCryst Pharmaceuticals |
2010-07-31 |
| NCT00499811 |
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT00499811 |
Completed |
National Cancer Institute (NCI) |
2011-08-31 |
| NCT00490776 |
Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00490776 |
Completed |
Novartis |
2009-09-30 |
| NCT00489203 |
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00489203 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-11-30 |
| NCT00438802 |
Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00438802 |
Completed |
Mayo Clinic |
2010-08-24 |
| NCT01093586 |
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01093586 |
Completed |
Case Comprehensive Cancer Center |
2015-12-31 |
| NCT00431912 |
A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00431912 |
Completed |
Onxeo |
2011-01-31 |
| NCT00425555 |
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00425555 |
Completed |
Novartis |
2013-06-30 |
| NCT00412997 |
LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00412997 |
Completed |
Novartis |
2008-05-31 |
| NCT00408681 |
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00408681 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-11-30 |
| NCT00799461 |
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications |
https://ClinicalTrials.gov/show/NCT00799461 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-11-30 |
| NCT00348985 |
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00348985 |
Completed |
National Cancer Institute (NCI) |
2010-01-31 |
| NCT00306969 |
Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00306969 |
Completed |
Boston University |
NA |
| NCT00293345 |
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00293345 |
Completed |
National Cancer Institute (NCI) |
2012-10-31 |
| NCT00255801 |
Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00255801 |
Completed |
Memorial Sloan Kettering Cancer Center |
2017-10-31 |
| NCT00221039 |
Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A |
https://ClinicalTrials.gov/show/NCT00221039 |
Completed |
M.D. Anderson Cancer Center |
2011-04-05 |
| NCT00211198 |
Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) |
https://ClinicalTrials.gov/show/NCT00211198 |
Completed |
Eisai Inc. |
2005-01-31 |
| NCT00182637 |
Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00182637 |
Completed |
Jonsson Comprehensive Cancer Center |
2010-09-30 |
| NCT00178841 |
Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL |
https://ClinicalTrials.gov/show/NCT00178841 |
Completed |
Vanderbilt University |
2007-03-31 |
| NCT00131937 |
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00131937 |
Completed |
National Cancer Institute (NCI) |
2011-09-30 |
| NCT00118352 |
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00118352 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-07-31 |
| NCT00112593 |
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer |
https://ClinicalTrials.gov/show/NCT00112593 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-11-30 |
| NCT00106431 |
A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL) |
https://ClinicalTrials.gov/show/NCT00106431 |
Completed |
Celgene |
2008-06-01 |
| NCT00099593 |
Immunization Against Tumor Cells in Sezary Syndrome |
https://ClinicalTrials.gov/show/NCT00099593 |
Completed |
FDA Office of Orphan Products Development |
NA |
| NCT00098891 |
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00098891 |
Completed |
National Cancer Institute (NCI) |
2008-03-31 |
| NCT00098332 |
Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00098332 |
Completed |
National Cancer Institute (NCI) |
2010-12-31 |
| NCT00091559 |
Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) |
https://ClinicalTrials.gov/show/NCT00091559 |
Completed |
Merck Sharp & Dohme Corp. |
2005-11-23 |
| NCT00089271 |
17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00089271 |
Completed |
National Cancer Institute (NCI) |
2010-06-30 |
| NCT00089011 |
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00089011 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-03-31 |
| NCT00003196 |
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT00003196 |
Completed |
Fred Hutchinson Cancer Research Center |
2002-04-30 |
| NCT00006251 |
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer |
https://ClinicalTrials.gov/show/NCT00006251 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-09-30 |
| NCT00005080 |
506U78 in Treating Patients With Lymphoma |
https://ClinicalTrials.gov/show/NCT00005080 |
Completed |
National Cancer Institute (NCI) |
2006-01-31 |
| NCT00080535 |
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT00080535 |
Completed |
National Institutes of Health Clinical Center (CC) |
2011-12-31 |
| NCT00005799 |
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer |
https://ClinicalTrials.gov/show/NCT00005799 |
Completed |
Fred Hutchinson Cancer Research Center |
2002-07-31 |
| NCT00078858 |
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00078858 |
Completed |
Fred Hutchinson Cancer Research Center |
2006-01-31 |
| NCT00077155 |
Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00077155 |
Completed |
National Cancer Institute (NCI) |
2010-06-30 |
| NCT00072514 |
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT00072514 |
Completed |
Fred Hutchinson Cancer Research Center |
2008-07-31 |
| NCT00071084 |
Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin. |
https://ClinicalTrials.gov/show/NCT00071084 |
Completed |
Emergent Product Development Seattle LLC |
2004-06-30 |
| NCT00071071 |
Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin. |
https://ClinicalTrials.gov/show/NCT00071071 |
Completed |
Emergent Product Development Seattle LLC |
2004-05-31 |
| NCT00003210 |
Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin’s Lymphoma or Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00003210 |
Completed |
National Cancer Institute (NCI) |
2003-11-30 |
| NCT00061880 |
BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00061880 |
Completed |
National Cancer Institute (NCI) |
2005-01-31 |
| NCT00050999 |
Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients |
https://ClinicalTrials.gov/show/NCT00050999 |
Completed |
Eisai Inc. |
2006-09-30 |
| NCT00049504 |
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00049504 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-03-31 |
| NCT00040846 |
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00040846 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-12-31 |
| NCT00030849 |
Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00030849 |
Completed |
National Cancer Institute (NCI) |
2004-09-30 |
| NCT00795769 |
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00795769 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-06-09 |
| NCT00025415 |
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT00025415 |
Completed |
National Cancer Institute (NCI) |
2005-01-31 |
| NCT00020072 |
Analysis of Genes Present in Cutaneous T-cell Lymphoma Cells |
https://ClinicalTrials.gov/show/NCT00020072 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00014235 |
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00014235 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-02-28 |
| NCT00004241 |
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma |
https://ClinicalTrials.gov/show/NCT00004241 |
Completed |
National Cancer Institute (NCI) |
2006-05-31 |
| NCT00003970 |
Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00003970 |
Completed |
National Cancer Institute (NCI) |
2003-10-31 |
| NCT00051012 |
Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT00051012 |
Completed |
Eisai Inc. |
2006-10-31 |
| NCT00001249 |
Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac |
https://ClinicalTrials.gov/show/NCT00001249 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00043420 |
CPG 7909 in Patients With Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00043420 |
Completed |
Pfizer |
2007-03-31 |
| NCT00038025 |
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT00038025 |
Completed |
M.D. Anderson Cancer Center |
2006-11-29 |
| NCT00051597 |
A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00051597 |
Completed |
Seattle Genetics, Inc. |
NA |
| NCT00007345 |
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00007345 |
Completed |
National Institutes of Health Clinical Center (CC) |
2015-01-26 |